Trial Profile
Multicenter, Open-label Study to Evaluate the Safety and Efficacy (by Blinded Reading) of Gadobutrol-enhanced Magnetic Resonance Angiography (MRA) After a Single Injection of 0.1 mmol/kg of Gadobutrol in Subjects With Known or Suspected Renal Artery Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2016
Price :
$35
*
At a glance
- Drugs Gadobutrol (Primary)
- Indications Renal artery thrombosis; Vascular disorders
- Focus Diagnostic use; Registrational
- Acronyms GRAMS
- Sponsors Bayer
- 06 May 2016 New trial record
- 29 Apr 2016 Primary endpoint has been met. (Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA)
- 29 Apr 2016 Primary endpoint has been met. (Sensitivity for Detection of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA)